
													
															
															Year
															DEALS // DEV.
															Country
															
															Therapeutic Area
															Study Phase
															Deal Type
															Product Type
															Dosage Form
															Lead Product
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Circurna
Deal Size : Undisclosed
Deal Type : Collaboration
Circurna Engages GATC Health for AI-Powered Discovery to Accelerate ciRNA Therapeutics
Details : The collaboration is designed to enhance the design, delivery, and targeting of Circurna’s next-generation RNA therapeutics.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
August 26, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Circurna
Deal Size : Undisclosed
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Certepetide,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Lisata Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lisata, GATC Use AI to Derisk and Accelerate Drug Development
Details : GATC’s MAT AI platform will analyze Lisata’s investigational drug, LSTA1 (certepetide), to identify optimized and derisked development opportunities across various indications.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
March 05, 2025
Lead Product(s) : Certepetide,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Lisata Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
